/
GRCE
$2.30-$0.08 (-3.36%)prev close
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$38.7M
16M shares
52-week range
$1.79 – $5.18
15% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
6.95%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-0.91
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $309.3K | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $3.1M | $0 | $119.9K | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$3.1M | $0 | $189.4K | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | 61.2% | — | — | — | — | — |
| R&D | $29.4M | $31.9M | $6.6M | $6.9M | $13.5M | $6.4M | $13.5M | $2.4M |
| Operating income | −$34.4M | −$48.8M | −$25.9M | −$19.5M | −$70.5M | −$17.4M | −$23.8M | −$11.1M |
| EBITDA | −$36.8M | −$45.9M | −$15.5M | −$19.2M | −$24.5M | −$15.4M | −$23.7M | −$11.1M |
| Net income | −$39.4M | −$51.0M | −$31.1M | −$12.3M | −$57.4M | −$17.4M | −$13.6M | −$7.8M |
| Net margin | — | — | -10039.8% | — | — | — | — | — |
| EPS (diluted) | -46.58 | -28.78 | -12.59 | -2.02 | -7.72 | -1.83 | -1.13 | -0.47 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $5M | $-0.52 | $-0.77–$-0.26 | 1 |
| 2028 | $1M | $-0.61 | $-0.69–$-0.54 | 2 |
| 2029 | $100M | $1.60 | $0.82–$2.38 | 1 |
| 2030 | $140M | $2.40 | $1.23–$3.57 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.70
Price
$2.30
Implied downside
-70%
Peer comparison
Grace Therapeutics, Inc. Common Stock
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
www.gracetx.com- Employees
- 5
- IPO / List date
- Apr 26, 2011
- HQ
- PRINCETON, NJ
Held by traders on TradeandTell
No one on the platform currently holds GRCE.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 243,910 | $1.1M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded GRCE yet.
